| parent | MOLPATH | LP7822-2 |
| child | Gene product metabolic activity interpretation | LP416494-5 |
| child | COMT gene product metabolic activity interpretation | LP411319-9 |
| child | CYP2B6 gene product metabolic activity interpretation | LP202923-1 |
| child | CYP2C19 gene product metabolic activity interpretation | LP202918-1 |
| child | CYP2C9 gene product metabolic activity interpretation | LP202920-7 |
| child | CYP2D6 gene product metabolic activity interpretation | LP202919-9 |
| child | CYP3A4 gene product metabolic activity interpretation | LP207955-8 |
| child | CYP3A5 gene product metabolic activity interpretation | LP202922-3 |
| child | CYP4F2 gene product metabolic activity interpretation | LP202924-9 |
| child | DPYD gene product metabolic activity interpretation | LP202927-2 |
| child | NAT2 gene product metabolic activity interpretation | LP202925-6 |
| child | NUDT15 gene product metabolic activity interpretation | LP410955-1 |
| child | TPMT gene product metabolic activity interpretation | LP203040-3 |
| child | UGT1A1 gene product metabolic activity interpretation | LP202926-4 |
| child | UGT2B15 gene product metabolic activity interpretation | LP229882-8 |
| child | SLCO1B1 gene product functional interpretation | LP202928-0 |
| child | Medication usage suggestion | LP213617-6 |
| child | Psychotropic medication pharmacogenomic analysis | LP417630-3 |
| child | Risk of adverse drug reaction sequence variation interpretation | LP411431-2 |
| PartDisplayName | en-US | MOLPATH.PHARMG |
| DisplayName | en-US | Pharmacogenomics |
LOINC Version: 2.77
FHIR